一系列证据表明钠葡萄糖共转运蛋白2抑制剂（SGLT-2i）可以护肾保心，对慢性肾脏病（CKD）有良好的治疗作用，即延缓估算肾小球滤过率（eGFR）下降、降低蛋白尿及全因死亡风险。那么，除了这些获益外，SGLT-2i对肾脏还有哪些益处呢？2024年10 ...

colorectal (colon) cancer; epidermal growth factor receptor (EGFR); RAS; liquid biopsy; rechallenge; cetuximab; RAS; ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

2024 年 12 月 6 日 - 8 日，欧洲肿瘤内科学会亚洲年会（ESMO Asia）将在新加坡盛大召开。本届会议将汇聚全球专家学者，集中展示和讨论肿瘤学领域的最新科学和临床进展，为肿瘤领域带来一场学术盛宴。此次会议中，「Dato-DXd ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...

A technology has been developed that can analyze tumor mutations in lung cancer patients to confirm drug resistance to ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

China’s drug regulator approved Alpha Biopharma Ltd.’s EGFR tyrosine kinase inhibitor (TKI), Zorifer (zorifertinib hydrochloride tablets; AZD-3759), as a first-line treatment for EGFR-mutated ...

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia ...

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...

EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, ...